Researchers
Tiago Mestre

Tiago Mestre

MSc MD

Scientist, Neuroscience

Ottawa Hospital Research Institute

Neurologist, Neurology

Medicine

Co-Director, Deep Brain Stimulation Program (Movement Disorders)

uOttawa Brain and Mind Research Institute

Associate Professor, Medicine

Neurology

OCRID https://orcid.org/0000-0002-6973-7479

Contact

tmestre@toh.on.ca

613798-5555 x 18986

Clinical Administration: Administrative Assistant 613-798-5555 X18986

Bio

Dr. Tiago Mestre is a physician with The Ottawa Hospital and a researcher with the Ottawa Hospital Research Institute and the uOttawa Brain and Mind Research Institute. He is currently leading the implementation of programs for treatment of advanced PD patients at the Ottawa Hospital including Deep Brain Stimulation and Duodopa. He leads a clinical research program in Movement Disorders focused in the area of drug development in areas of need, development of better outcomes for clinical trials and optimization of drug development from a preclinical to a first-in-human and confirmatory stages, fostering collaborations intra and extra-mural with basic neuroscience and clinical research groups. The different lines of research include the conduction of investigator-initiated clinical trials in Parkinson Disease, the study of placebos and expectation of benefit using Parkinson Disease as a model, identification of clinical phenotypes applicable to clinical research in PD and development of prediction rules for incident PD. He is interested in the development of novel paradigm of care delivery in PD, transposable to other chronic neurodgenerative disorders. As leader of the Deep Brain Stimulation program is interested in the development of novel paradigms of stimulation.

Research Goals and Interests

My clinical research interests include clinical trial methodology, development of new treatment for non-motor symptoms in Parkinson’s disease as well as biomarker development in neurodegenerative parkinsonisms.

• A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of GLYCOpyrrolate for moderate-to-severe sialorrhea in PARkinson’s disease - GLYCOPAR.   ROLE: Principal Investigator (2014) 

• Use of high resolution isotropic/three dimensional magnetic resonance imaging as a biomarker for the early distinction of Parkinson’s Disease from Atypical Parkinsonian Disorders.  ROLE: Principal Investigator (2014) 

• Lessebo effect in Parkinson’s disease. ROLE: Principal Investigator (2010 – current) 

• Clinical significant changes in advanced Parkinson’s disease patients using the intravenous levodopa model. ROLE: Principal Investigator (2010 – current) 

• Intravenous levodopa as a means of assessing severity of dyskinesia and duration of wearing-off in Parkinson’s disease patients. Clinimetric properties of commonly used dyskinesia rating scales. ROLE: Co-Investigator. (2010 – current)

• Biomarkers of PD risk in LRRK2 mutation carriers. ROLE: Co-investigator (2012 – current)

• Biomarkers in Huntington’s Disease - Systematic review on the topic and definition of guidelines for validation of biomarkers in Huntington’s disease. ROLE: Principal investigator (2012 – current)

News

Related Research at The Ottawa Hospital